Study of IMC-11F8 in Participants With Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

Official title:

Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00835185
• Other study ID #: 13926
• Secondary ID: 2006-003147-23CP
• Status: Completed
• Phase: Phase 2
• First received: February 2, 2009
• Last updated: December 21, 2015
• Start date: August 2007
• Est. completion date: October 2010

Study information

• Verified date: December 2015
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationBelgium: Federal Agency for Medicinal Products and Health ProductsSpain: Agencia Española de Medicamentos y Productos Sanitarios
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).

Description:

The purpose of this study is to evaluate the anti-tumor activity (best overall response) of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody IMC-11F8 administered in combination with mFOLFOX-6 chemotherapy regimen in treatment-naive, locally-advanced or metastatic CRC participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: October 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically-confirmed, EGFR-detectable or EGFR-undetectable CRC

• Locally-advanced unresectable or metastatic adenocarcinoma of the colon or rectum

• At least 1 unidimensional-measurable target lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI); target lesion(s) must not lie within an irradiated area

• Age =18 years

• Life expectancy of =6 months

• Eastern Cooperative Oncology Group (ECOG) performance status =2 at study entry

• Adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) =1.5 x 10^9 liter (L), hemoglobin =10 grams per deciliter (g/dL), and platelets =100 x 10^9/L

• Adequate hepatic function as defined by a total bilirubin =1.5 milligrams per deciliter (mg/dL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x upper limit of normal (ULN) (or 5.0 x ULN in the case of liver metastases), and alkaline phosphatase (AP) =2.5 x ULN (or 5.0 x ULN in the case of liver metastases)

• Adequate renal function as defined by a serum creatinine =1.5 x ULN, creatinine clearance = 60 milliliters per minute (mL/min), or serum albumin =lower limit of normal (LLN)

• Participant's relevant toxicities/effects of prior therapy [surgery/radiation therapy (RT)] must have recovered to a stable or chronic level

• Participant agrees to use adequate contraception during the study period and for 4 weeks after the last dose of study treatment. Participants must notify the principal investigator if they themselves or their partner becomes pregnant.

• Participant has provided signed Informed Consent

Exclusion Criteria:

• Has received prior systemic chemotherapy for locally-advanced unresectable or metastatic CRC.

• Has received prior radiotherapy to >25% of bone marrow

• Has documented and/or symptomatic brain metastases

• Has participated in clinical studies of non-approved experimental agents or procedures within 12 weeks of study entry

• Has received previous therapy with monoclonal antibodies

• Has received previous therapy with any agent that targets the EGFR

• Has serious concomitant medical conditions including active uncontrolled infection or cardiac disease, which in the opinion of the investigator, could compromise the participant or study.

• On chronic non-topical corticosteroid treatment for >6 months at doses >10 milligrams per day (mg/day) of prednisolone or equivalent before study entry, which in the opinion of the investigator could compromise the participant or the study

• Has a known dihydropyrimidine dehydrogenase deficiency

• Has a known allergy to any of the treatment components

• Has an acute or subacute intestinal occlusion

• Has peripheral neuropathy =Grade 2

• Has a history of other malignancies, with the exception of curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix

• If female, is pregnant (confirmed by urine or serum beta human chorionic gonadotropin test) or breast-feeding

• Has received a prior autologous or allogeneic organ or tissue transplantation

• Has interstitial pneumonia or interstitial fibrosis of the lung

• Has pleural effusion or ascites that causes =Grade 2 dyspnea

• Has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of Informed Consent

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Biological:
• IMC-11F8 (necitumumab)
IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1

Drug:
• Oxaliplatin
Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
• Folinic acid (FA)
FA 400 mg/m² IV infusion bolus injection
• 5-FU
5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours

Locations

Country	Name	City	State
Belgium	ImClone Investigational Site	Brussels
Belgium	ImClone Investigational Site	Haine Saint-Paul
Spain	ImClone Investigational Site	Barcelona
Spain	ImClone Investigational Site	Madrid
Spain	ImClone Investigational Site	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

Belgium,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )	CR and PR defined using Response Evaluation Criteria In Solid Tumors (RECIST) version (v) 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions and PR defined as a =30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD. Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence) / (total number of participants treated) * 100.	Up to 30 Months	No
Secondary	Overall Survival (OS)	OS was defined as the duration from the date of first dose to the date of death from any cause. OS was estimated by the Kaplan-Meier method. Participants who were alive at the time of the data inclusion cutoff or lost to follow-up, OS was censored at the last contact.	First dose to date of death from any cause up to 30 months	No
Secondary	Progression-Free Survival (PFS)	PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. Progressive disease (PD) was determined using RECIST v1.0 criteria. PD was defined as =20% increase in the sum of LD of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of new lesions and/or unequivocal progression of existing nontarget lesions. PFS was estimated by the Kaplan-Meier method. Participants who had no PD or death at the time of the data inclusion cutoff, PFS was censored at their last tumor assessment prior to the earliest of the following events: 2 or more missed visits, additional cancer treatment or the end of the follow-up period.	First dose to measured PD or death up to 30 months	No
Secondary	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) or Death	The number of participants who experienced AEs, SAEs or death during the study and within 30 days of last dose. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.	First dose to end of treatment and 30-day post treatment follow-up up to 31 months	No
Secondary	Duration of Response	The duration of response was defined as the time from first confirmed CR or PR to the first time of PD or death due to any cause. CR, PR and PD were defined using RECIST v1.0 criteria. CR was defined as the disappearance of all target and non-target lesions; PR was defined as a =30% decrease in the sum of the LD of the target lesions, taking as reference the baseline sum of the LD; PD was defined as a =20% increase in the sum of LD of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of new lesions and/or unequivocal progression of existing nontarget lesions. Participants with CR or PR who had no PD or death at the time of the data inclusion cutoff, the duration of response was censored at their last contact.	Time of response to time of measured PD or death up to 30 months	No
Secondary	Serum Anti-IMC-11F8 Antibody Assessment (Immunogenicity)	A participant was considered to have an anti-IMC-11F8 response if there were 2 consecutive positive samples or if the final sample tested is positive. Participants with a baseline sample positive for anti-IMC-11F8 antibodies were considered unevaluable for immunogenicity. A sample was considered positive for IMC-11F8 antibodies if it exhibited a post-baseline treatment emergent antibody level that exceeded the upper 95% confidence interval of the mean determined from the normal anti-IMC 11F8 level found in healthy treatment-naïve individuals.	Baseline up to last day of treatment plus 45 days after last treatment (127 weeks)	No
Secondary	Maximum Concentration (Cmax) of IMC-11F8 at Study Day 1 of Cycle 1		Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose	No
Secondary	Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-8)] of IMC-11F8 at Study Day 1 of Cycle 1		Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose	No
Secondary	Half-Life (t1/2) of IMC-11F8 at Study Day 1 of Cycle 1	The t1/2 is the time measured for the plasma concentration of the drug to decrease by one half.	Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose	No
Secondary	Clearance (CL) of IMC-11F8 at Study Day 1 of Cycle 1	CL is the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time.	Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose	No
Secondary	Volume of Distribution (Vss) of IMC-11F8 at Study Day 1 of Cycle 1	Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug at steady-state.	Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose	No
Secondary	Cmax at Study Day 1 of Cycles 2 Through 6		Day 1 Cycles 2 through 6 predose and 1 hour postdose	No
Secondary	Area Under the Curve (AUC) at Study Day 1 of Cycles 2 Through 6		Day 1 Cycles 2 through 6 predose and 1 hour postdose	No
Secondary	t1/2 at Study Day 1 of Cycles 2 Through 6		Day 1 Cycles 2 through 6 predose and 1 hour post dose	No
Secondary	CL at Study Day 1 of Cycles 2 Through 6		Day 1 Cycles 2 through 6 predose and 1 hour postdose	No
Secondary	Vss at Study Day 1 of Cycles 2 Through 6		Day 1 Cycles 2 through 6 predose and 1 hour postdose	No
Secondary	Change From Baseline in Tumor Size		Baseline, 29 Months	No
Secondary	Kirsten Rat Sarcoma (KRAS) Mutation Status	Tumor tissues collected prior to study drug administration were evaluated for the presence or absence of KRAS mutations by a retrospective analysis.	Baseline	No